TxCell is exclusively developing regulatory T cells that are specific of a single antigen.
As shown below, our general process starts with a simple leukapheresis. From this sample, we produce antigen-specific Treg cells and then expand them before injecting them back to the patient.
Our platform has the potential to address a wide range of severe inflammatory and autoimmune disorders with unmet medical needs. TxCell is targeting transplantation as well as a range of autoimmune diseases (both T-Cell and B-Cell mediated) such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel diseases or inflammatory skin diseases.
The antigen specificity comes from the CAR receptor as shown below.
After their isolation from the blood of patients, Treg cells are genetically modified by transduction with Chimeric Antigen Receptors (CAR). The CAR introduced into Treg cells is designed to allow Treg cell activation and immuno-modulation through in vivo recognition of a protein present in inflamed areas in patients suffering from autoimmune and chronic inflammatory diseases.
TxCell develops several candidates in parallel with a focus on multiple sclerosis as well as novel approaches to target pathogenic cells
TxCell’s objectives are: to file a first CTA and/or IND for its most advanced CAR-Treg program, generate additional preclinical proof-of-concept data with its CAR-Treg programs in autoimmunity and inflammation and secure long-term financing solution. A number of these programs are being developed through collaboration agreements with leading international academic laboratories, such as the University of British Columbia (UBC) in Canada, the Lübeck Institute of Experimental Dermatology (LIED) in Germany and the Center for Research in Transplantation and Immunology (CRTI) in Nantes (France).